Table 2.

Time to retreatment in the phase I randomized controlled trial and open-label extension study (safety population)

Number of treatment courses received	Time to retreatment (months)	Maintenance groupa (n = 38)	Switch groupb (n = 20)
2 (1st course in RCT and 2nd course in OLE)	Between 1st and 2nd course	15.40 ± 2.60	15.30 ± 2.25
3 (1st and 2nd course in RCT and 3rd course in OLE)	Between 1st and 2nd course	8.75 ± 1.41	8.92 ± 1.27
	Between 2nd and 3rd course	8.14 ± 1.20	7.99 ± 1.15

Values are mean ± standard deviation

OLE open-label extension, RCT randomized controlled trial, RTX innovator rituximab

^aPatients treated with CT-P10 during the preceding phase I RCT and also during the OLE study

^bPatients treated with RTX during the preceding phase I RCT and with CT-P10 during the OLE study